The drug discovery platform developer will support its growth with new funding from investors including SIG and Legend Capital.

China-based drug discovery platform developer StoneWise has received $100m of series B and B-plus funding from investors including quantitative trading firm Susquehanna International Group, DealStreetAsia reported yesterday. The series B round was led by Legend Capital, the venture capital firm formed by conglomerate Legend Holdings, while fellow VC firm Lightspeed China and Chinese state-backed private…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.